gsk201402106k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--


 




Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons.


I give below details of an increase in interests in Ordinary Shares in GlaxoSmithKline plc on 9 January 2014 in respect of the personal holding of the under-mentioned person, following the purchase of shares at a price of 1651.50 pence per share, as a result of a re-investment of the dividend paid to shareholders on 9 January 2014.
 
PDMR
Ordinary Shares
Ms C Thomas
33.853

The Company was informed of this transaction on 10 February 2014.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

Sonja Arsenić
Corporate Secretariat

 
10 February 2014
 



 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 10, 2014 
 
 
By: SIMON BICKNELL
------------------
 
 
Simon Bicknell
Authorised Signatory for and on
behalf of GlaxoSmithKline plc